234 related articles for article (PubMed ID: 36334189)
1. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
3. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
5. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
6. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
7. A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer.
Cao L; Xiang G; Liu F; Xu C; Liu J; Meng Q; Lyu S; Wang S; Niu Y
Cancer Chemother Pharmacol; 2019 Sep; 84(3):609-620. PubMed ID: 31297554
[TBL] [Abstract][Full Text] [Related]
8. Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer.
Pizon M; Lux D; Pachmann U; Pachmann K; Schott D
J Transl Med; 2018 Dec; 16(1):356. PubMed ID: 30547831
[TBL] [Abstract][Full Text] [Related]
9. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
[TBL] [Abstract][Full Text] [Related]
10. ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.
Heckler MM; Thakor H; Schafer CC; Riggins RB
FEBS J; 2014 May; 281(10):2431-42. PubMed ID: 24684682
[TBL] [Abstract][Full Text] [Related]
11. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen Resistance: Emerging Molecular Targets.
Rondón-Lagos M; Villegas VE; Rangel N; Sánchez MC; Zaphiropoulos PG
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548161
[TBL] [Abstract][Full Text] [Related]
13. ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network.
Qian H; Ji R; Shen C; Wei Y; Sheng C; Ni Q; Pan J; Chi Y; You H; Miao Y; Shi M; Huang X; Shen A
Aging (Albany NY); 2023 Dec; 15(24):14996-15024. PubMed ID: 38126976
[TBL] [Abstract][Full Text] [Related]
14. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
[TBL] [Abstract][Full Text] [Related]
15. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
16. AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors.
Rangel N; Rondon-Lagos M; Annaratone L; Aristizábal-Pachon AF; Cassoni P; Sapino A; Castellano I
Cells; 2020 Apr; 9(4):. PubMed ID: 32344660
[TBL] [Abstract][Full Text] [Related]
17. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Madhavan S; Gusev Y; Singh S; Riggins RB
J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
[TBL] [Abstract][Full Text] [Related]
18. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
[TBL] [Abstract][Full Text] [Related]
19. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer.
Kim JY; Park K; Lee E; Jung HH; Ahn JS; Im YH; Park WY; Park YH
Oncotarget; 2017 Jan; 8(5):8693-8706. PubMed ID: 28060723
[TBL] [Abstract][Full Text] [Related]
20. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
